EA202091082A1 - Композиция и способ лечения периферической т-клеточной лимфомы и кожной т-клеточной лимфомы - Google Patents

Композиция и способ лечения периферической т-клеточной лимфомы и кожной т-клеточной лимфомы

Info

Publication number
EA202091082A1
EA202091082A1 EA202091082A EA202091082A EA202091082A1 EA 202091082 A1 EA202091082 A1 EA 202091082A1 EA 202091082 A EA202091082 A EA 202091082A EA 202091082 A EA202091082 A EA 202091082A EA 202091082 A1 EA202091082 A1 EA 202091082A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cell lymphoma
peripheral
treatment
skin
composition
Prior art date
Application number
EA202091082A
Other languages
English (en)
Inventor
Сваруп Кумар Венката Сатья Ваккаланка
Original Assignee
Ризен Фармасьютикалз Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ризен Фармасьютикалз Са filed Critical Ризен Фармасьютикалз Са
Publication of EA202091082A1 publication Critical patent/EA202091082A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к применению двойного селективного ингибитора протеинкиназы PI3K-дельта и гамма, такого как (S)-2-(1-((9H-пурин-6-ил)амино)пропил)-3-(3-фторфенил)-4H-хромен-4-он (соединение (A), также известное как теналисиб), или его фармацевтически приемлемой соли или фармацевтической композиции, содержащей такой ингибитор, для лечения периферической Т-клеточной лимфомы (PTCL) и кожной Т-клеточной лимфомы (CTCL).
EA202091082A 2017-12-06 2018-12-05 Композиция и способ лечения периферической т-клеточной лимфомы и кожной т-клеточной лимфомы EA202091082A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741043740 2017-12-06
PCT/IB2018/059680 WO2019111185A1 (en) 2017-12-06 2018-12-05 Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma

Publications (1)

Publication Number Publication Date
EA202091082A1 true EA202091082A1 (ru) 2020-10-23

Family

ID=65012059

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091082A EA202091082A1 (ru) 2017-12-06 2018-12-05 Композиция и способ лечения периферической т-клеточной лимфомы и кожной т-клеточной лимфомы

Country Status (15)

Country Link
US (1) US20200289520A1 (ru)
EP (1) EP3720557A1 (ru)
JP (1) JP2021505571A (ru)
KR (1) KR20200096781A (ru)
CN (1) CN111770776A (ru)
AU (1) AU2018378415A1 (ru)
BR (1) BR112020011167A2 (ru)
CA (1) CA3084905A1 (ru)
CL (1) CL2020001482A1 (ru)
CO (1) CO2020006886A2 (ru)
EA (1) EA202091082A1 (ru)
IL (1) IL275028A (ru)
MX (1) MX2020005771A (ru)
SG (1) SG11202005208QA (ru)
WO (1) WO2019111185A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6499165B2 (ja) * 2013-06-07 2019-04-10 ライゼン・ファーマシューティカルズ・エスアー 二重選択的ｐｉ３デルタ及びガンマキナーゼ阻害剤
EP4149629A1 (en) * 2020-05-14 2023-03-22 Rhizen Pharmaceuticals AG Purine derivatives as sik-3 inhibitors
CN117222413A (zh) * 2021-02-10 2023-12-12 同润生物医药(上海)有限公司 治疗肿瘤的方法和组合
KR20230045895A (ko) * 2021-09-29 2023-04-05 사회복지법인 삼성생명공익재단 말초 t세포 림프종 예후 예측용 신규 바이오마커 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
KR20070055625A (ko) 2002-12-16 2007-05-30 제넨테크, 인크. 이뮤노글로불린 변이체 및 이들의 용도
CA2779574C (en) * 2009-11-05 2018-12-18 Rhizen Pharmaceuticals S.A. Novel kinase modulators
JP6499165B2 (ja) * 2013-06-07 2019-04-10 ライゼン・ファーマシューティカルズ・エスアー 二重選択的ｐｉ３デルタ及びガンマキナーゼ阻害剤

Also Published As

Publication number Publication date
WO2019111185A1 (en) 2019-06-13
US20200289520A1 (en) 2020-09-17
BR112020011167A2 (pt) 2020-11-17
CN111770776A (zh) 2020-10-13
AU2018378415A1 (en) 2020-07-23
SG11202005208QA (en) 2020-07-29
KR20200096781A (ko) 2020-08-13
IL275028A (en) 2020-07-30
JP2021505571A (ja) 2021-02-18
CL2020001482A1 (es) 2020-11-20
CA3084905A1 (en) 2019-06-13
EP3720557A1 (en) 2020-10-14
MX2020005771A (es) 2020-10-28
CO2020006886A2 (es) 2020-08-31

Similar Documents

Publication Publication Date Title
EA202091082A1 (ru) Композиция и способ лечения периферической т-клеточной лимфомы и кожной т-клеточной лимфомы
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
BR112018071585A2 (pt) formulações de um inibidor de lsd1
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
EA202091711A1 (ru) ГЕТЕРОЦИКЛИЛАМИНОЗАМЕЩЕННЫЕ ТРИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ
BR112016030541A2 (pt) métodos para o tratamento de infecções fúngicas
PL417066A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
CR20210281A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr
EA202193015A1 (ru) Ингибиторы cdk
EA201790838A1 (ru) Ингибитор киназы aurora a
MD3341379T2 (ro) Inhibitori ai EZH2
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2021006520A (es) Compuestos heteroaromaticos como inhibidores de vanina.
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
BR112022008365A2 (pt) Inibidores de cd73
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
WO2017098051A3 (en) Combined preparations of pkm2 modulators and hmgb1
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения